(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of 144.19% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Praxis Precision Medicines's revenue in 2023 is $1,932,000.On average, 5 Wall Street analysts forecast PRAX's revenue for 2023 to be $17,002,900, with the lowest PRAX revenue forecast at $16,283,019, and the highest PRAX revenue forecast at $19,111,122. On average, 1 Wall Street analysts forecast PRAX's revenue for 2024 to be $6,856,008, with the lowest PRAX revenue forecast at $6,856,008, and the highest PRAX revenue forecast at $6,856,008.
In 2026, PRAX is forecast to generate $854,258,597 in revenue, with the lowest revenue forecast at $42,850,050 and the highest revenue forecast at $2,193,236,959.